Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes

Research output: Contribution to journalReview articlepeer-review

137 Scopus citations

Abstract

Both as monotherapy and in combination with other OHAs, timed bromocriptine (Cycloset) causes a 0.6-0.7%reduction in HbA1c and reduces plasma triglyceride and FFA concentrations in type 2 diabetic patients. In a 52-week safety study, Cycloset decreased the cardiovascular composite end point by 40%. Other advantages of Cycloset include absence of hypoglycemia since insulin secretion is not stimulated, weight neutrality, no need for dose adjustment in patients with moderate renal insufficiency, lack of edema and CHF, and good side effect profile.

Original languageEnglish (US)
Pages (from-to)789-794
Number of pages6
JournalDiabetes care
Volume34
Issue number4
DOIs
StatePublished - Apr 2011

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes'. Together they form a unique fingerprint.

Cite this